The biological product sales in the U.S. have shown varying trends from 2013 through 2023, with sales rising from $23.987 billion to $33.044 billion. The period saw fluctuations, including a noticeable dip in 2014 and 2022, and significant growth in 2015 and 2021. The CAGR over the last five years stood at 2.54%. Projected sales from 2024 to 2028 reflect modest but steady growth, with a forecasted CAGR of 1.74% and an overall growth rate of 9.02% over the period.
Future trends to watch for include:
• Potential impacts of new biological product launches and FDA approvals.
• Market dynamics influenced by competitive biosimilars and pricing strategies.
• Technological advancements and their adoption in biologics manufacturing.
• Regulatory landscape changes and healthcare policy shifts.
